Skip to main content

Uncommonly Rare

How one of the rarest neurodegenerative diseases could lend insight into ubiquitous neuroprotective processes

Written byKerry Grens
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00

CHAPERONE PROBLEMS: One of the NCL patients Milen Velinov and colleagues studied had characteristic storage inclusions in peripheral lymphocytes (a). Another showed similar inclusions in cells throughout the central nervous system (b).DOI:10.1371/JOURNAL.PONE.0029729.G002Kufs disease type B, also called autosomal dominant adult neuronal ceroid lipofuscinosis (ANCL), is a particularly nefarious malady, even as neurodegenerative conditions go. Beginning in young adulthood, people with the disease develop dementia, difficulty with movement, and changes in personality. After a decade or so of cognitive decline, Kufs patients succumb, rarely making it to their 45th birthday.

Other forms of NCL even strike children, affecting about one in 12,500 globally. But the adult form of the disease is exceptionally rare, with fewer than 200 cases reported worldwide, says Milen Velinov, who treats patients with NCL at Albert Einstein College of Medicine and directs the Genetic Services program at the New York State Institute for Basic Research in Developmental Disabilities, both in New York City.

From genetic studies in recent years it had become clear that NCL is actually a cluster of diseases with different genetic roots, but “we did not have any idea what the gene of this condition [ANCL] is,” says Velinov. A few years ago, he and his colleagues set out to find the genetic culprits. Not knowing where to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile

Related Topics

Published In

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Improving rAAV Production for Viral Vector Manufacturing

Improving rAAV Production for Viral Vector Manufacturing

cytiva logo
Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Miltenyi
Scientist holding a clear 384-well PCR microplate in a laboratory

What Dictates PCR Success Before Amplification Begins?

Integra Logo
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems

Products

Sino Biological Logo

Sino Biological Launches European Newsletter Campaign with Exclusive Welcome Gifts

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo